InsidersTradesSigma
Track the ROIVANT SCIENCES LTD stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €26.3bn. The latest transaction was reported on 29 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MELISSA EPPERLY. Every trade is free.
Analysts rate ROIVANT SCIENCES LTD Strong Buy (bullish), based on 11 analysts. Average price target: US$41.82.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
ROIVANT SCIENCES LTD is a biopharmaceutical company focused on developing innovative treatments for serious diseases. It employs a technology-driven approach to accelerate drug research and development.